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The convergence of advances in medical science, human biology, data science and 
technology has enabled the generation of new insights in the phenotype known as 
“diabetes”. Increased knowledge of this condition has emerged from populations around the 
world, illuminating the differences in how diabetes presents, its variable prevalence, and how 
best practice in treatment vary between populations. In parallel, focus has been placed on 
the development of tools for the application of precision medicine to numerous conditions. 
This Consensus Report presents the ADA Precision Medicine in Diabetes Initiative, its 
mission, current state of the field, and prospects for the future. This report provides expert 
opinions on areas of precision diagnostics and precision therapeutics (including prevention 
and treatment), as well as highlighting key barriers and opportunities to implementation of 
precision diabetes medicine around the globe in a way that enables better care and 
outcomes for all those in need. There are clear cases where precision diagnosis is already 
feasible and effective (monogenic forms of diabetes) and others where major hurdles remain 
for global implementation (in complex forms of diabetes). The situation is similar for precision 
therapeutics, in which the appropriate therapy will often change over time owing to the 
manner in which diabetes evolves within individual patients. This report describes a 
foundation for precision diabetes medicine, while highlighting what remains to be done to 
realise its potential. This, combined with a subsequent, detailed evidence-based review (due 
2022) will provide a roadmap for precision medicine in diabetes that helps improve the 
quality of life for all those with diabetes.  
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Rationale for Precision Medicine in Diabetes 
The practice of medicine centers on the individual. From the beginning, the physician has 
examined the patient suffering from illness, ascertained his/her signs and symptoms, related 
them to the medical knowledge available at the time, recognized patterns that fit a certain 
category and, based on the practical wisdom accumulated via empirical trial and error, 
applied a given remedy that is best suited to the situation at hand. Thus, the concept of 
precision medicine, often defined as providing the right therapy, for the right patient at the 
right time, is not novel. What has changed radically is our ability to characterize and 
understand human biological variation through 1) assessment of the metabolic state, 2) 
leveraging data to inform disease categories, and 3) science-guided preventive and 
treatment decisions tailored to specific pathological conditions. Coupling these with detailed 
information accessible through digital devices and technologies about lifestyle and the 
environment, as well as data abstracted from electronic medical records, present 
unparalleled opportunities to optimize diabetes medicine. 
Diabetes mellitus is diagnosed by the emergence of hyperglycemia, the crossing of a 
threshold of blood glucose concentration beyond which, if chronically unchecked, results in 
microvascular and macrovascular end-organ complications. However, hyperglycemia is the 
end-product of numerous pathophysiological processes that often emerge over many years 
and converge on the inability of the pancreatic beta cells to secrete enough insulin to meet 
the demands of target tissues, often because the amount of available insulin is no longer 
effective. In clinical practice, absolute insulin deficiency can be detected from the 
autoimmune destruction of beta cells in type 1 diabetes (T1D), which comprises ~10% of all 
diabetes. Making the diagnosis of T1D is critical, given the therapeutic requirement of 
exogenous administration of insulin. In more specialized settings, hyperglycemia might be 
detected from an inherited or de novo loss of function in a single gene (e.g., monogenic 
diabetes, comprising 2-3% of all diabetes diagnosed in children or young adults). Diabetes 
can also appear after pancreatitis or organ transplantation, during pregnancy, or as a result 
of cystic fibrosis. The remaining 85-90% of individuals with diabetes, however, are likely 
diagnosed as having type 2 diabetes (T2D), which will have manifest through defects in one 
or (more often) multiple pathways (e.g., beta cell insufficiency, fat accumulation or 
miscompartmentalization, inflammation, incretin resistance, dysfunction of insulin signaling). 
Our modern capacity to comprehensively interrogate diverse axes of biology has facilitated 
the approach of studying an individual to infer general principles, from which a discrete 
treatment plan is selected. These axes include developmental/metabolic context, genomic 
variation, chromatin signals that mark genes as active or repressed in tissues, expressed 
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transcripts, biomarkers of disease and increased knowledge of lifestyle/environmental risk 
factors. Parallel advances in computational power and analytic methods required to 
appropriately interrogate ’big data’ are driving insights that may radically transform the 
practice of medicine. Yet, at this time, the individual physician often lacks time and training to 
incorporate this into medical decision making. Thus, the translation of the rapidly 
accumulating new knowledge into practice requires careful evaluation and translational 
strategies involving specialist training, education and policy considerations. 
The failure to adequately understand the diverse molecular and environmental processes 
that underlie diabetes and our inability to identify the pathophysiological mechanisms that 
trigger diabetes in individual patients, limit our ability to prevent and treat the disease. Public 
health strategies have struggled to slow the epidemic, even in countries with the greatest 
financial and scientific resources. Pharmacologic therapies, comprising 12 different drug 
classes currently approved by the Food and Drug Administration (FDA) 
(www.fda.gov/media/91130/download), may, at best, control glycemia and modify disease 
course, but not provide a cure or result in the remission of disease. Moreover, these agents 
are sometimes prescribed based on non-medical considerations (cost, side effects, patient 
preference, or comorbidities) which may overlook the biological mechanism. Thus, more 
people are developing diabetes worldwide and progressing to complications, incurring a 
significant health care burden and cost. 
There are, however, several reasons for hope. First, diabetes caused by single gene defects 
can be characterized and targeted therapies are particularly effective (1; 2). Second, islet 
autoantibody biomarkers and genomic risk have clarified autoimmune diabetes from other 
forms of the disease (3; 4), thereby facilitating immune-intervention trials, pre-onset 
monitoring to reduce risk of severe complications, and aid in detection of environmental 
triggers (5). Third, multiple biomarkers and genetic variants have been shown to alter risk of 
T2D, revealing previously unsuspected biological pathways and providing new targets. 
Fourth, T2D has been shown to be a complex combination of multiple conditions and 
processes, defined by process-specific subgroups in which individuals with extreme burdens 
of risk in particular pathways reside and for whom a specific therapeutic approach may be 
optimal (6). Finally, the tools, resources and data now exist to determine the biological and 
lifestyle/environmental predictors of drug response, as measured by a variety of clinical 
outcomes (7).  
What is the Precision Medicine in Diabetes Initiative (PMDI)? 
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The idea of precision diabetes medicine is gaining momentum, based upon the promise of 
reducing the enormous and growing burden of diabetes worldwide. To address this, the 
PMDI was launched in 2018 by the American Diabetes Association (ADA), in partnership 
with the European Association for the Study of Diabetes (EASD). The PMDI has partnered 
subsequently with other organizations (the USA National Institute of Diabetes, Digestive and 
Kidney Diseases (NIDDK)).  
The mandate of the PMDI is to establish consensus on the viability and potential 
implementation of precision medicine for the diagnosis, prognosis, prevention and treatment 
of diabetes, through expert consultation, stakeholder engagement and systematic evaluation 
of available evidence. This mandate is pursued in order to realize a future of longer, healthier 
lives for people with diabetes. 
The PMDI is focused on assessing evidence, promoting research, providing education, and 
developing guidelines for the application of precision medicine in diabetes. The 2019 ADA 
Scientific Sessions (June 2019) sponsored a research symposium focused on precision 
medicine, followed by a PMDI Stakeholder Meeting (October 2019) that was attended by 
experts in areas germane to precision diabetes medicine from around the world. Future 
PMDI symposia will extend the themes of precision diabetes medicine during the 2020 ADA 
and EASD Scientific Sessions. In the coming years, educational approaches to translate the 
science into practice will be the target of a series of postgraduate education symposia. A 
global clinical research network focused on precision diabetes medicine is also being 
planned, along with other education and dissemination activities (see Figure 1 for overview of 
key objectives).  
The purpose of the work underlying the ADA/EASD Precision Medicine in Diabetes 
consensus reports, of which this is the first, is to define relevant terminology (see Text Box 1) 
and overview the current status of diagnostics and therapeutics (prevention and treatment) in 
diabetes, including key areas of opportunity and where further inquiry is needed (see Text 
Boxes 2-4). Particular focus is placed on elucidating the etiological heterogeneity of diabetes, 
which involves a combination of approaches including contemporaneous measures of risk 
factors, biomarkers and genomics, as well as lifestyle and pharmacologic interventions. 
Monogenic diabetes is one of few areas where precision diabetes medicine has been proven 
feasible and is practiced (overviewed in detail in the Diabetes Care Expert Forum (ref)). This 
first consensus report does not seek to address extensively the role of precision medicine in 
the complications of diabetes and is a topic for future evaluation. In addition, we do not 
discuss diabetes digital device technology, as this is addressed in a joint ADA/EASD 
consensus report (8; 9). A second PMDI consensus report will be published documenting the 
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findings of a systematic evidence review, focusing on precision diagnostics and precision 
therapeutics (prevention and treatment). 
An Executive Oversight Committee, comprised of representatives from the founding 
organizations, ADA (LP) and EASD (JJN), and the two co-chairs of the initiative (PWF and 
SSR), provide PMDI governance. The Executive Oversight Committee is responsible for 
ensuring the PMDI activities are executed. Leadership and direction of the PMDI are 
provided by members of the PMDI Steering Committee, currently comprised of academic 
leaders in precision diabetes medicine from the United States (WKC, JCF, JMN) and Europe 
(ATH, MIM, ERP), a representative from NIDDK (CGL), and the Executive Oversight 
Committee members (LP, JJN, PWF, SSR). The Steering Committee is responsible for 
providing guidance for PMDI activities and engages in developing precision diabetes 
medicine education, drafting consensus statements, and building interest/working groups to 
achieve its mission. The Executive Oversight Committee and the Steering Committee work 
closely together under the banner of the PMDI Taskforce. Membership of the Steering 
Committee will expand to include experts from around the world and across multiple areas of 
expertise germane to the topic of precision diabetes medicine. 
Work for this consensus report began at the October 2019 Stakeholder Meeting in Madrid. 
The meeting included presentations and roundtable discussions. At the conclusion of the 
meeting, a writing group meeting attended by the PMDI Taskforce and stakeholders was 
held to determine what should be addressed in the consensus report. Following the meeting, 
consensus was reached by the PMDI Taskforce through bimonthly calls and electronic 
communication. Relevant experts outside of the Taskforce were asked to contribute sections 
as needed. The consensus report was then peer-reviewed by experts in the field and by the 
clinical committees of the participating organizations. The report was then submitted to 
Diabetes Care, Diabetologia, and The Journal of Clinical Endocrinology & Metabolism for 
simultaneous publication.  
Precision Diabetes Medicine: What It Is and What It Is Not (see Text box 1) 
 
Precision diabetes medicine refers to an approach to optimize the diagnosis, prediction, 
prevention or treatment by integrating multi-dimensional data, accounting for individual 
differences. The major distinction from standard medical approaches is the use of complex 
data to characterize the individual’s health status, predisposition, prognosis, and likely 
treatment response. These data may stem from traditional sources such as clinical records, 
as well as from emergent sources of ‘big data’ such as individual medical records from very 
large cohorts of patients, geo-mobility patterns obtained from devices, behavioral monitors 
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(e.g., actigraphy for exercise and sleep assessments), ingestible, subcutaneous or wearable 
sensors (e.g., for blood glucose monitoring), and genomic and other ‘omics data. Integration 
of patient preferences, patient-centered outcomes, cost-effectiveness, and shared decision-
making will guide how precision diabetes medicine is formulated and applied.  
There are several terms sometimes used interchangeably with precision medicine, including 
personalized medicine, individualized medicine, and stratified medicine. The 2020 ADA 
Standards of Medical Care in Diabetes (ADA SMCD) places considerable emphasis on the 
personalization of diabetes medicine, highlighting that “clinicians care for patients and not 
populations” [S2] (10). This reflects the realization of individual differences with respect to 
symptomatology, presentation, behaviors, preferences, social circumstances, response to 
treatment, comorbidities, or clinical course. For precision diabetes medicine to be effective, it 
must be tailored to the individual. Thus, the ADA SMCD instructs the clinician to adapt 
guidelines to each patient’s characteristics, circumstance, and preferences, including the 
patient’s food security, housing, and financial stability. In the context of the PMDI, this is not 
considered to be precision medicine; rather, this final step in the process of translating 
knowledge into practice is personalized (or individualized) medicine. In contrast, precision (or 
stratified) medicine emphasizes tailoring diagnostics or therapeutics (prevention or 
treatment) to subgroups of populations sharing similar characteristics, thereby minimizing 
error and risk while maximizing efficacy. Included within precision diabetes medicine is the 
monitoring of disease progression using advanced technologies or how patient features 
affect the reliability of assays. The application of precision diabetes medicine may 
substantially reduce errors in the diagnostic (Figure 2), therapeutic (Figure 3) and prognostic 
(Figure 4) processes. For example, the interrogation of large sets of longitudinal clinical data 
could identify disease subtypes and match the patient to others with a similar disease profile; 
through knowledge of treatment efficacy and outcomes, more precise prognosis and 
optimization of therapies for this patient by concordance to similar subgroups would emerge 
(see Text box 3 and figure 3). 
Precision Diagnostics (see Text Box 2) 
What are the Requirements for Precision Diagnosis? 
Precision diagnostics employs methods to sub-classify patients to enable the successful 
application of precision medicine approaches (Figure 2). This will facilitate matching precise 
prevention strategies and treatments to individuals either at risk of or diagnosed with 
diabetes. Ideally, a precision diagnostic test should be: (i) robust (high test-retest reliability 
within and between laboratories); (ii) able to define a discrete subgroup giving insights into 
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disease etiology, prognosis, and treatment response; (iii) widely available; (iv) easily 
performed with accepted norms for interpretation; and (v) inexpensive (or at least cost-
effective).  
Precision diagnosis can be conceptualized as a pathway, rather than a single step, that 
moves through stages. The diagnostic stages include assessing the: 
• Expected prevalence based on epidemiology, including age, or age at diagnosis of 
diabetes, sex and ancestry,  
• Probable clinical diagnosis using clinical features and other data, and  
• Modification by diagnostic tests that are interpreted in the light of prevalence and 
diagnosis  
A diagnosis in precision medicine is a probability-based decision, typically made at a point in 
the natural history of a disease, reflecting neither an absolute truth nor a permanent state. 
Presenting the degree of uncertainty in a manner that is intuitive to the patient and 
practitioner is critical if the precision diagnosis is to be effective.  
Precision Diagnosis in Clinical Practice  
Data and outcomes from the widespread use of glycated hemoglobin, rather than blood 
glucose levels, for diagnosis has led to a precision approach for the diagnosis of diabetes.  
The level of glycated hemoglobin will depend on factors that impact hemoglobin and red cell 
stability as well as average glucose values (10).  Genetic testing can reveal unsuspected 
variants that alter HbA1c. In African Americans, for example, heterozygosity for the HbS 
variant may lower HbA1c by ~0.3% ((11), and one or two copies of the minor allele at the X-
linked glucose-6-phosphate dehydrogenase G202A variant (found in ~11% of African 
Americans) lowers HbA1c by ~0.7% (12). Thus, knowledge of the patient’s ancestry and 
specific genetic information can guide interpretation of assay results and diabetes 
management 
DIAGNOSING T1D vs T2D.  Currently, the most common precision diagnosis that is made in 
clinical diabetes medicine is the classification of T1D versus T2D, the two most prevalent 
sub-categories with different etiologies and different treatment requirements. Part of the 
diagnostic dilemma is that neither T1D nor T2D are monolithic entities and robust “gold 
standards” are not universally agreed. Diagnostic issues arise when expected clinical 
features are discordant from established norms (e.g., people diagnosed with diabetes who 
are young and obese, or old and slim, or are a rare subtype in that clinical setting) (13). Islet 
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autoantibody positivity varies by clinical setting (e.g., in people without diabetes, patients 
diagnosed with probable T1D as children, and patients with clinical features of T2D), 
resulting in an altered prior probability of T1D that reflects the different prevalence in these 
diverse settings. The best diagnosis depends on integrating all diagnostic modalities, as 
demonstrated in predicting long term C-peptide negativity in patients diagnosed with diabetes 
between 20 and 40 years of age, where an integrated model outperformed clinical features, 
circulating antibodies or genetics used in isolation (3). The misdiagnosis of T1D and T2D in 
middle-aged and elderly adults (13; 14) suggest that precise diagnostic approaches are 
needed, especially as failure to recognize insulin-deficient states can be fatal. 
DIAGNOSING MONOGENIC DIABETES.  An Expert Diabetes Forum report (ref) has 
concluded recently that a monogenic diabetes diagnosis is closest to meeting all criteria for a 
perfect diagnostic test as it defines a discrete subgroup giving insights into etiology, 
prognosis, and treatment response (1; 2). Perhaps the best example of precision diabetes 
medicine is the excellent and long-lasting glycemic response to oral sulfonylureas in insulin-
dependent infants with neonatal diabetes when diagnosed to be due to abnormalities in the 
beta cell potassium channel (15-17).  In MODY, it is established that GCK patients do not 
require (18), or respond to, oral medication (19). Other MODY diagnoses (HNF1A, HNF4A 
and ABCC8) are acutely sensitive to the glucose-lowering effects of sulfonylureas (20-22); 
however, unless the diagnosis is precise, these therapeutic benefits are lost. With the clear 
benefits of precision diagnosis of monogenic diabetes, it is important to reduce diagnostic 
barriers to its implementation. For example, the cost of performing molecular genetic testing 
is high and universal testing is not cost-effective. It is thus necessary to limit testing to those 
most likely to have a monogenic diagnosis. Moreover, identification protocols require pre-
screening based on clinical features (e.g., family history, age at onset, phenotype including 
syndromic features) and non-genetic testing (islet autoantibodies and C-peptide).  
One approach for implementing precision medicine in the case of monogenic diabetes is: 
 
• Test all patients diagnosed with diabetes in the first 6 months of age, because >80% 
have a monogenic cause of neonatal diabetes 
• Use a MODY calculator to identify those whose clinical features suggest a high 
likelihood of MODY (www.diabetesgenes.org/mody-probability-calculator/) (23)  
• Test pediatric diabetes cases when at least three islet autoantibodies are antibody 
negative (24) 
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The effective use of these pre-genetic selection criteria should greatly improve the likelihood 
of correctly diagnosing monogenic diabetes and not have the burden of costly genetic 
screens. Although diagnostic molecular genetic testing utilizes robust analysis of germline 
DNA, which is virtually unchanged throughout life, there are still issues with its 
implementation. One issue is through errors of interpretation of the genetic information, 
leading to inaccurate identification of causal mutations in both clinical practice and in the 
published research literature (25). Curation of pathogenic variants for monogenic diabetes is 
critical and is currently being addressed by international consortia. Technological advances 
have resulted in testing multiple causes of monogenic diabetes in a single next-generation 
sequencing test. This approach is generally advantageous as it does mean syndromic 
monogenic diabetes is diagnosed genetically when the patient presents with isolated 
diabetes.  This will allow other features to be examined and treated appropriately before 
clinical presentation. Examples of this are neonatal diabetes (2) HNF1B (RCAD) (26), WFS1 
(Wolfram syndrome) (27) and mitochondrial diabetes (28).  For these patients, the genetic 
diagnosis of diabetes will have implications far beyond the prognosis and care of diabetes, 
as the patient with certain types of monogenic diabetes will also be at high risk of 
developmental delay, neurological disease, developmental kidney disease, liver failure, 
deafness and cardiomyopathy.  
DIAGNOSING LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA). LADA is not 
currently recognized by the ADA as a formal subtype of diabetes. Nevertheless, LADA 
reveals some of the difficulties in diabetes subtyping. It was shown that the presence of GAD 
autoantibodies in patients with T2D was associated with progression to early insulin therapy 
(29); yet, controversy remains whether LADA is a discrete subtype, a milder form of T1D, or 
a mixture of T1D and T2D (sometimes termed “type 3 diabetes”, where some patients with 
T1D also develop T2D). The uncertainty is increased by variation in the diagnostic criteria, 
with initial treatment based upon physician preference as well as the patient’s disease (30). 
In addition, there is variation in the level of GAD autoantibodies required for positivity that 
alters the diagnosis (31). 
SUBCATEGORIES OF COMMON FORMS OF DIABETES. The subcategorization of T1D or 
T2D may not always be the optimal approach for precision diabetes diagnosis or therapy. 
Nevertheless, the ability to delineate T1D or T2D using non-traditional data and approaches 
may lead to improvements in its prevention or treatment, including diabetes 
subclassifications beyond T1D or T2D.  
Subcategories in T1D 
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The age at which the initial islet autoantibody appears and the type of autoantibody (e.g., 
which of the four primary antibodies among ICA512, Ins, GAD, ZnT8) may be important in 
defining etiological subtypes of T1D (32). Data supporting this potential subcategory are 
based upon those diagnosed in the first 10 years of life and in predominantly white European 
populations. The relevance to other ethnic groups and those diagnosed later in life is 
uncertain.  
The majority of the genetic risk of T1D is now known, and the sensitivity and specificity of 
T1D genetic risk scores (T1D-GRS) both exceed 80% (5; 33-35); however, a high T1D-GRS 
will have low positive predictive value in populations with typically low prevalence. The 
greatest utility of a T1D-GRS may require integration with clinical features and islet 
autoantibodies (3; 4). There is variation in the genetic susceptibility with age at diagnosis but, 
at present, genetics is not suggested as an approach to defining subtypes of T1D. 
There is strong evidence for enrichment of immune cell types that are associated with 
genetic risk of T1D, particularly T cells (CD4+ and CD8+) and B cells (CD19+). However, at 
present, there is no immune-based test sufficiently reproducible and robust that it can be 
used diagnostically for T1D.  
Persistent, endogenous beta cell function in T1D is associated with greater potential for 
improved glycemic control and reduced complications (36). A stimulated C-peptide 
measurement represents a candidate for defining subcategories of T1D with different 
treatment aims. C-peptide levels exponentially fall in the honeymoon period after T1D 
diagnosis (37) but have been shown to be stable 7 years after diagnosis (38). Persistent C-
peptide is associated with a later age of diagnosis, although there are few data to predict 
those likely to maintain high levels of C-peptide. 
Subcategories in T2D 
Family history in T2D, as a surrogate for precise genetic evaluation, fails to meet many of the 
criteria of a robust test as any assessment changes over time and depends on the relatives 
selected for reporting the “family”. The value of a family history may be greatest in 
monogenic diabetes, in which a pedigree will often demonstrate a pattern of inheritance 
consistent with a single gene disorder and a consistent phenotype. 
T2D treatment response and disease progression can be predicted from continuous clinical 
features with specific models. These models appear to perform better than dividing into 
cluster based subgroups (7). An advantage of using clinical features is that they are widely 
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available and easily obtained (e.g., sex, BMI, HbA1c); however, a limitation is that clinical 
features may vary over time and with the natural history of the disease. Incorporation of 
longitudinal change with treatment response could be a strength as the model’s prediction 
would change in concert with changes in the patient’s phenotype. 
Recent research has attempted to define subcategories of T2D (and T1D) based on cluster 
analysis at diagnosis to provide insights into likely progression, risk of complications, and 
treatment response (39; 40). Barriers facing this and other approaches include collection of 
data that are not routinely obtained (e.g., a fasting C-peptide at the time of diagnosis with 
assay variability (41)) and the change in biomarkers over time that are dependent on disease 
course or its treatment. Genetic data has been used to define T2D subcategories by 
clustering genetic variants that associate with physiologic traits and which are correlated with 
clinical outcomes (6). At this time, the available genetic data for T2D and the clustering does 
not have sufficient predictive accuracy to replace existing delineative approaches. None of 
the methods described above are established for subclassification of T2D in clinical practice; 
nevertheless, it is true that in a minority of patients, their specific type of diabetes may be 
adequately characterized using genetic clustering (42; 43). 
Precision Therapeutics (see Figure 3) 
Careful diagnosis is necessary for successful precision therapy, whether for prevention or 
treatment. This is true where subgroup(s) of the population must be defined to determine 
which targeted interventions will be applied, as well as for determination of treatment 
outcome. In monogenic diabetes, there are no currently known options for prevention. In 
T1D, precision prevention involves mainly the optimization of monitoring methods (see Text 
Box 3), thereby facilitating early detection, prevention of onset complications, and optimizing 
treatment. In contrast, T2D has many avenues for prevention; thus, the possibilities for 
precision approaches, possibly through tailoring of lifestyle (e.g., diet), are broad in T2D.  
Precision Prevention in Diabetes (see Text Box 3) 
PRECISION PREVENTION IN T1D: T1D is characterized by damage, impairment, and 
eventual destruction of the insulin-producing pancreatic beta cells, thought to be the result of 
an autoimmune process. T1D progression has been grouped into discrete “stages” (44). 
Stage 1 is defined by the presence of ≥2 islet autoantibodies, with normal blood glucose. 
Stage 2 is defined by the presence of >2 islet autoantibodies with elevation of blood glucose, 
signaling the functional impairment of the beta cells. Stage 3 is characterized by symptoms 
of dysglycemia, such as polyuria or diabetic ketoacidosis, although not all symptoms need be 
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present. A clinical diagnosis of T1D typically is not given until Stage 3. T1D is nearly 
inevitable once >2 islet autoantibodies appear, particularly in those of younger age, with a 
lifetime diabetes risk approaching 100% (45; 46). Approximately one half of the risk of T1D is 
due to genetic factors, with over 30% of the genetic risk attributable to genes of the human 
leukocyte antigen (HLA) complex but also including more than 50 non-HLA loci (35). 
Unknown environmental factors are thought to trigger the autoimmune process that results in 
initial beta cell damage and progression toward symptomatic T1D (47). 
Primary prevention trails in genetically-susceptible individuals who have not yet developed 
autoantibodies (i.e., pre-Stage 1) and secondary prevention trials in children with Stages 1 
and 2 have been conducted (48) using dietary interventions and immune-targeting 
approaches. Dietary manipulation studies have been largely unsuccessful in reducing islet 
autoimmunity (49-51) or T1D (52). Previous intervention studies among individuals at Stage 
1 or Stage 2 have been unable to slow, halt, or reverse the destruction of insulin-producing 
beta cells.  Of nine completed secondary prevention trials (53-60), only one (using an anti-
CD3 antibody) has shown a slight delay in progression to T1D (61). 
Most prevention trials in T1D have not been effective, partially because the individual’s 
unique T1D genetic risk profile and their unique response to the preventive agent (immune 
therapy or dietary intervention) have not been considered. For example, the inflammatory 
response to infection with enteroviruses implicated in the onset of T1D has been shown to be 
genetically mediated (62) and diet has had different effects on development of autoimmunity 
and progression to T1D (63) dependent upon genetic risk. Several studies have suggested 
that susceptibility to islet autoimmunity and progression to T1D may be related to the ability 
to adequately use vitamin D, as higher cord blood 25(OH)D was associated with a decreased 
risk of T1D, but only in children who were homozygous for a vitamin D receptor gene (VDR) 
variant (64). Risk of islet autoimmunity was observed with reduced dietary intake of the 
omega-3 fatty acid, alpha-linolenic acid, but only in those with a specific genotype in the fatty 
acid desaturase gene (FADS) cluster (65). Thus, without considering the unique genetic 
profiles of children, dietary supplementation may not be successful, arguing for an 
appropriately validated precision approach. 
PRECISION PREVENTION IN T2D: The emergence of T2D as a global public health crisis 
during recent decades has motivated numerous large randomized controlled trials assessing 
the efficacy of pharmacologic or lifestyle interventions for prevention. An emphasis has been 
placed on intervening in people with “prediabetes,” defined as a person with levels of fasting 
blood glucose, 2-hr blood glucose, or HbA1c that are chronically elevated but below the 
diagnostic thresholds for diabetes. Although prediabetes is a major risk factor for T2D and 
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other diseases (66), intervening in everyone with prediabetes may not be cost-effective (67). 
Aggressive precision prevention in those with relevant risk factors is discussed in the current 
ADA SMCD (68). Youth with prediabetes should be the focus of preventive interventions, 
especially those who are overweight or obese, and with one or more additional risk factors 
(e.g., maternal history or exposure to gestational diabetes mellitus (GDM), a positive family 
history of diabetes in first- or second-degree relatives, signs of insulin resistance, or of 
specific high-risk ancestry). 
Multiple interventions in T2D have been evaluated for risk reduction and prevention, both in 
the short- and the long-term. A recent systematic review (69) reported that after active 
interventions lasting from 6 months to >6 years, lifestyle relative risk reduction (39%) was 
similar to that from use of drugs (36%); however, only lifestyle interventions had a sustained 
reduction in risk once the intervention period ended. The post-intervention follow-up (~7 
years) demonstrated a lifestyle risk reduction of 28% compared to a non-significant reduction 
(5%) from drug interventions.  
Most lifestyle intervention programs use standardized approaches designed to change diet 
and exercise habits for reducing body weight. The Diabetes Prevention Program (DPP) 
evaluated the efficacy of lifestyle intervention and metformin therapy, compared with 
standard of care and placebo, for delay or prevention of diabetes in those with impaired 
glucose regulation at baseline. Although reductions in diabetes risk from lifestyle (58% 
reduction) and metformin (31% reduction) compared with the control intervention were 
impressive (70), there was considerable variation across the study population (71), with 
many participants developing T2D during the active intervention period (the first 2.8 years of 
the trial). Thus, the DPP lifestyle intervention did not truly "prevent" diabetes. Indeed, in the 
decade after randomization, during which participants were offered lifestyle reinforcement 
semi-annually, the average duration before disease onset was ~3 years (72). Those 
participants in the DPP who progressed most rapidly were those who lost the least weight in 
the early stages of the intervention (73), with genetic variants representing significant 
predictors of peak weight loss and weight loss maintenance (74). Results from the DPP and 
other large prevention trials suggest a “one-size-fits-all” lifestyle intervention strategy will not 
be efficacious for all, particularly if it cannot be sustained, strengthening the case for 
precision lifestyle interventions in T2D prevention. 
Although precision diabetes medicine is much more than genetics, the majority of relevant 
research has focused on evaluating the role of genetic variants in precision prevention. Large 
epidemiological studies (75) and intervention trials (76; 77) strongly suggest that standard 
approaches for lifestyle modification are equally efficacious in preventing diabetes regardless 
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of the underlying genetic risk. This contrasts the extensive epidemiological evidence 
suggesting that the relationship of lifestyle with obesity is conditional on genetic risk (78-81); 
however, with few exceptions (e.g., (74)), analyses in large randomized controlled trials have 
failed to show that these same genetic variants modify weight loss in response to lifestyle 
intervention (82). It is also important to recognize that knowledge of increased genetic risk for 
diabetes may not motivate improvements in lifestyle behaviors. Indeed, knowledge of 
increased genetic risk for diabetes may decrease motivation to modify behavior in genetic 
fatalists (83).  
Diet recommendations optimized to the individual have been shown to reduce postprandial 
glycemic excursions to a greater extent than standard approaches in healthy individuals (84). 
Meal compositions that induce the most favorable glycemic profiles have been guided by 
models derived from an individual’s biological data (e.g., microbiome, genome, and 
metabolome) lifestyle factors (e.g., sleep and exercise) and postprandial glycemia following 
the consumption of a series of standardized meals. Although these studies indicate that 
personalized diet plans may help minimize postprandial glycemic excursions, no studies 
have reported the long-term impact on glycemic control of adhering to personalized diets.  
Of the 12 approved classes of diabetes drugs (www.fda.gov/media/91130/download), many 
having been assessed for efficacy in prevention. Overall, drugs that enhance insulin action 
have proven more effective in diabetes prevention than those that increase insulin secretion. 
Some of the variability in the diabetes-reducing effect of metformin in the DPP has been 
associated with variation in the SLC47A1 gene that encodes the multidrug and toxin 
extrusion 1 transporter protein (85). In the DPP Outcomes Study, the effects of lifestyle, 
metformin and placebo interventions were assessed in weight reduction during the 6–15 
years that followed the end of the randomized intervention phase (86). As a percentage of 
baseline weight, those assigned to metformin maintained an average 6.2% weight loss, 
compared to the lifestyle intervention group which maintained a 3.7% weight loss, and the 
placebo group that maintained a 2.8% weight loss. In the subgroup of DPP participants who, 
at one-year post-randomization, lost <5% baseline weight (poor responders), body weight 
during the following 14 years remained essentially unchanged, whether receiving metformin 
or placebo interventions. In contrast, those participants in the lifestyle intervention group who 
lost <5% baseline weight gained and sustained ~2 kg excess body weight in the years that 
followed. This findings reveal a subgroup of DPP participants in whom lifestyle intervention 
led to weight gain, which presents a potential avenue for stratified intervention, where 
individuals who are unlikely to respond well to lifestyle modification might be better served by 
other therapeutic approaches. 
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Precision treatment in diabetes (see Text Box 4) 
Once diabetes develops, there are a number of therapeutic steps clinically indicated to 
improve disease management. These steps include:  
• Glucose monitoring 
• Patient education and lifestyle intervention (87)  
• Surgery 
• Drug treatments to lower HbA1c  
• Drug treatments to lower cardiovascular risk (e.g., statins, anti-hypertensives) 
• Drug treatments targeted at specific complications (e.g., ACEi/ARB and SGLT2i for 
proteinuric kidney disease, fibrates for retinopathy, and atypical analgesics for painful 
neuropathy) 
For each of these treatments, there will be patients who respond well and those who respond 
less well, in addition to those who have adverse outcomes from the therapy. Thus, precision 
treatment can be considered as using patient characteristics to guide the choice of an 
efficacious therapy to achieve the desired therapeutic goal or outcome, while reducing 
unnecessary side effects (figure 3). Given the broad scope of precision treatment, 
pharmacological therapy in T2D has the best evidence-base for precision therapeutics at 
present.    
Subcategories and Drug Outcomes 
Traditionally, trials of therapeutic intervention do not recognize variation in etiologic 
processes that lead to development of T2D. The MasterMind consortium recently re-
analyzed data from the ADOPT and RECORD studies in order to highlight how clinical 
phenotype can be used to help guide treatment intervention. On average, men who were 
non-obese had greater HbA1c reduction over 5 years with sulfonylureas than they did with 
thiazolidinediones; however, women with obesity had sustained HbA1c-lowering over the 5 
years compared to sulfonylureas (88). When considering the clinical and physiological 
parameters used to subgroup individuals with diabetes (39), the insulin-resistant cluster 
defined in ADOPT and RECORD responded better to thiazolidinediones while the older 
patient cluster responded better to sulfonylureas (88). This increasingly granular view of T2D 
will lead to increasing precision therapeutic paradigms requiring evaluation and potential 
implementation.   
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The most current examples of precision therapeutics can be seen in monogenic diabetes, for 
which single gene mutations are causal for the development of diabetes and for which 
targeted treatments can, in effect, bypass the etiological defect (e.g., sulfonylurea sensitivity 
in HNF1A MODY (20) and insulin independence with high-dose sulfonylureas in neonatal 
diabetes due to KATP channel defects (16)). Genetic variation not only can capture etiological 
variation (i.e., genetic variants associated with diabetes risk) but also variation in drug 
pharmacokinetics (absorption, distribution, metabolism, excretion – ADME) and in drug 
action (pharmacodynamics). As T2D is a common complex disease characterized by 
thousands of etiological gene variants, it remains uncertain that individual variants will be 
identified that are highly predictive of drug outcomes in T2D. In contrast, there are examples 
of small-to-modest magnitude effects of genetic variants in HbA1c response to diabetes 
treatments (e.g., 0.5% difference in HbA1c reduction with metformin based upon SLC2A2 
rs8192675 genotype (89)), with the largest effects seen affecting variation in ADME genes 
(e.g., CYP2C9 genotype and sulfanylurea response (90); CYP2C8 and SLCO1B1 genotypes 
and rosiglitazone response (91)). These data highlight the potential of genetic information to 
be incorporated into clinical decision support tools to guide a precision therapeutics 
approach.   
The diabetes phenotype is markedly different across ethnic groups; thus, it is likely that drug 
outcomes will differ between populations. The current and growing burden of diabetes is 
growing rapidly in all populations, particularly South and East Asians, yet, these populations 
are under-represented in clinical and drug outcome trials. A lack of systematic reviews and 
meta-analyses from these high-prevalence regions still points to differences in drug 
response. For example, the DPP4i response is greater in Asians than Whites (92), a result 
supported by a subgroup analysis of TECOS showing a greater HbA1c reduction to 
sitagliptin in East Asians compared to Whites (93). Glycemic response to metformin has also 
been reported to differ by ethnic group, with African American individuals having greater 
response than European Americans (PMID: 24921653).   
Precision Approaches in Diabetes Pregnancy  
In women, being affected by gestational diabetes mellitus (GDM) is a major risk factor for 
T2D. The risk of developing T2D in women with prior GDM approaches 70% after the index 
pregnancy (94), climbing to 84% developing T2D in women of East Indian ancestry (95). 
Currently, genetic studies of GDM have identified those variants known to increase risk of 
T2D (96); however, other variants have been shown to influence glycemic traits specifically in 
pregnancy (97). Furthermore, like T2D, GDM is a heterogeneous condition linked to primary 
defects in either insulin secretion or sensitivity (98; 99). Attempts to develop models to 
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predict pregnancy complications (100) or subsequent T2D (101) in GDM using clinical 
characteristics, biomarkers, and/or genetic variants have yet to be adopted, even though 
both lifestyle interventions and metformin use have demonstrated benefits in reducing the 
risk of T2D in women with prior GDM (102). 
The target for all patients with T1D or T2D in pregnancy is to achieve as near normal glucose 
as possible, particularly around conception (to reduce developmental anomalies) and in the 
third trimester (to reduce the risk of macrosomia; (103). In pregnancy, the only clear 
exception so far is for mothers with MODY2 (mutations in the GCK gene) as fetal growth is 
determined predominantly by fetal genotype (104).In mothers whose fetus inherits the 
mother’s GCK mutation, fetal growth is normal despite the maternal hyperglycaemia and 
treatment of the maternal hyperglycaemia is not recommended (104; 105). Establishing 
whether the fetus is likely to be affected is determined usually by ultrasound scan. In the 
future, the use of non-invasive cell-free DNA methods in maternal blood will likely establish 
fetal risk (106).  In GDM, whether maternal hyperglycaemia is closely monitored and treated 
in the third trimester is based on the degree of hyperglycaemia as shown by an oral glucose 
tolerance test at 24-28 weeks gestation (10) In the future, this decision could be modified by 
non-glycaemic factors that impact fetal growth. 
Patient-first, Mental Health, and Quality of Life Outcomes (see Text Box 5) 
Precision diabetes medicine holds the promise of reducing uncertainty by providing therapies 
that are more effective, less burdensome and with fewer adverse outcomes, which ultimiately 
improve quality of life and reduce premature death.  Of high relevance in this context is 
mental health (e.g., risk of distress and depression), yet little has been done to investigate 
how precision medicine might play a useful role.   
Depression and anxiety are twice as common in people with diabetes compared to the 
general population, occurring in up to 20% of adult patients (107). Distress occurs in ~30% of 
people with diabetes (110), as a separate and related psychological symptom, reflecting the 
emotional and psychological burden that comes with diabetes and its complications, the life 
adjustments it requires, and anxiety about hypoglycemia or the impact on the fetus for 
gestational diabetes.  Distress has been reported as more common in patients in secondary, 
rather than primary care, as well as in non-European ancestry populations.  Depression is 
more common in lower- and middle-income countries, the location for ~75% of people with 
T2D (108). Both depression and distress in diabetes are more common in those who 
progress from oral agents to insulin therapy (109). The onset of complications with the 
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initiation of a more complex pattern of treatment is associated with increased rates of 
depression (109).  
There are key points in the life-course of the person with diabetes when both rational and 
irrational fears are often elevated, typically coinciding with “events”, including:  
• Increased medication dose 
• Transition to insulin or other injectables or devices 
• Emergence of complications or worsening of complications  
• Following a severe hypoglycemic event  
• Change in diabetes provider  
In many cases, patient self-evaluations may be distorted at these times because the patient 
attributes blame for the disease to his/her self, the future feels uncertain and distress peaks.  
In the setting of precision diabetes medicine, providers should assess symptoms of diabetes 
distress, depression, anxiety, disordered eating, and cognitive capacities using appropriate 
standardized and validated tools at the initial visit, at periodic intervals, and when there is a 
change in disease, treatment, or life circumstance (110), information that, when combined 
with other data, are likely to improve the precision of clinical decision making.  
Psychological counseling can help patients understand and manage their emotional 
reactions to major events by developing a more optimistic outlook and a more realistic, 
modulated and adaptive emotional reactions (111). Precision medicine may be used in the 
future to help predict the frequency and extent of emotional crises. As a result, precision 
diabetes medicine may lessen the patient burden, objectivize their disease, and provide 
targets for behavioral and point-of-care interventions at critical moments in the clinical care 
cycle. Effective and tailored education and professional counselling will be necessary to 
mitigate the risk that a clearer prognosis may raise anxiety about the future for some 
patients.  
Equity in Precision Diabetes Medicine 
The experience with monogenic diabetes has shown that there is a large degree of regional, 
national, and international variation in how, and how often, these cases are diagnosed (1; 
112; 113). This variation is, in part, due to differences in access to general medical care and 
treatments, access to relevant healthcare professionals with the necessary education, 
training, and experience, and access to laboratories with the necessary experience, assays 
and standards (114). A precision approach to diabetes care will require that the relevant 
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laboratory methods and assays are carefully standardized and comparable. Standardized 
assays include:  
• T1D-associated autoantibodies  
• C-peptide  
• Clinical genetic/genomic assays  
• Decision-support interpretation  
A challenge is that the frequency of various diabetes phenotypes and risk genotypes may 
vary by regions of the world and between ethnicities within a region. For example, T2D often 
manifests very differently in Native Americans than in people of European ancestry, with 
Native Americans tending to develop diabetes at a much younger age and experience loss of 
beta cell function earlier in the life-course of the disease (115). Recent insights following the 
ADA Precision Diabetes Medicine meeting in Madrid (October 2019) confirm that case-based 
interactive learning is an excellent way to support this type of postgraduate education for 
clinicians at all levels of training. 
The Road to Implementation 
Advances in science allow for generation of large-scale biologic and physiologic data that 
can be harnessed for precision diagnostic (Figure 2), therapeutic (Figure 3) and prognostic 
(Figure 4) purposes. Strategies to integrate and analyze such data should provide increased 
understanding of the pathophysiology of diabetes and its apparent heterogeneity. Programs 
are needed to train, foster and retain individuals with biologic and data science expertise who 
will contribute to precision diabetes medicine efforts. Furthermore, clinicians, scientists, and 
regulators must collaborate to develop standards and safeguards for protecting the 
accumulated ‘precise’data, which in some instances may lead to unintended and sensitive 
revelations, on individuals in a secure manner across populations and across countries.  
Inclusion of understudied populations are needed within the cohorts studied in precision 
diabetes medicine research for development of precision diagnostics and therapeutics. There 
are known regional and country-specific dietary habits and food sources. While a 
Mediterranean diet rich in olive oil and nuts has shown to be efficacious in preventing 
diabetes (116; 117), it is not safe to assume that incorporating this diet will be as efficacious 
or well-adopted in other countries. While lifestyle modification is efficacious for preventing 
diabetes, it is difficult to sustain, and harnessing the expertise of behavioral and social 
scientists to study how individuals from different backgrounds and communities can best 
sustain lifestyle change behaviors is needed.  
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Diagnosis of diabetes may vary in different populations based on subtype frequency or 
genetic differences. Diagnostic studies should be conducted in different populations to obtain 
necessary data to tailor screening criteria based upon the prevalence of diabetes subtypes. 
In addition, a series of personal and societal barriers exist in the implementation of precision 
prevention across geographic regions and countries. 
The communication strategy used by the interventionalist and the patient’s perception of risk 
may be important factors contributing to the successful implementation of precision diabetes 
medicine. While there are clear possibilities for the use of genetics in the precision 
prevention of T2D, focusing on other non-genetic biomarkers will enhance precision 
prevention strategies. A series of challenges will exist in T1D, particularly as there is 
currently no intervention in the disease process, while there is an accepted treatment (i.e., 
insulin). Yet, appropriate lifestyle change (e.g., diet, exercise) to reduce the risk of 
complications remains difficult to achieve.  
Precision prevention may aid the adoption of behavioral modification through individual goal-
based behavioral change, a process that is currently both labor-intensive and costly. The 
Food4Me Study, a European initiative focused on personalized nutrition, suggests that 
including genetic feedback into online nutritional guidance may improve dietary habits more 
than conventional diet advice (118). Despite wide-spread dissemination of more pragmatic 
programs and payor coverage, evaluation of uptake and engagement in various programs 
and tailoring of them, requires routine and rigorous administration.  
Precision diabetes medicine will require careful evaluation. Leveraging large-scale, real-
world evidence and federated clinical trial data using unbiased approaches may facilitate the 
identification of relevant subgroups or unique characteristics with differential prognosis or 
therapeutic response. Real-world evidence may also provide the benefit of including patient 
subgroups that have been excluded from trials to better understand efficacy and risk for 
these patients. Cost-effectiveness studies of importance to payors to support screening 
practices or therapies for subgroups may require simulations under different assumptions 
and regional conditions. Discussions with various regulatory agencies will be needed to 
determine the level of evidence needed for regulatory approval and adoption of precision 
diagnostics and therapeutics.  
Diagnoses and therapeutic devices that incorporate multilevel data that may be analysed 
using articifical intelligence methods (e.g., machine learning) will require strategies to ensure 
that algorithms are robust and reproducible, requiring consensus for regulatory bodies to 
deem a surrogate outcome as “acceptable”. Similar discussions are needed to determine 
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acceptable outcomes of relevance to patients (i.e., ‘patient-reported outcomes’). There are a 
growing number of biobanks linked with clinical information in health care systems, as well as 
efforts to combine these biobanks. The amount and diversity of data required for 
understanding and predicting individual patients’ risks and therapeutic responses is likely to 
overwhelm the general provider caring for a patient with diabetes unless the data is cafefully 
articulated. Thus, development of tools and strategies to synthesize such data and to 
facilitate shared decision making will be needed to translate evidence for precision diabetes 
medicine into individualized diabetes care, accounting for patient preferences and behaviors, 
health literacy and socioeconomic considerations. Pragmatic studies of decision support 
systems utilizing rich information in these health care systems, particularly those with 
biobank linked electronic health care records, are needed to guide implementation of 
precision diabetes medicine into clinical practice and to generate the much needed cost-
efficacy data for broader adoption. 
There is an enormous amount of work needed to move the field of precision diabetes 
medicine forward. The critical partnerships must be established between the scientific 
community, patients, health care systems, providers, payors, industry and regulatory bodies 
involved in the development, evaluation, approval, adoption and implementation of precision 
diagnostics, monitoring and therapeutics that are deemed acceptable for safe, efficacious 
and cost-effective use in precision diabetes care.  
Building Partnerships 
If precision medicine is the future of diabetes care, it will represent a clear progression from 
current and established clinical practice, owing mainly to the possibilities to characterize the 
patient, the disease and the disease processes in greater detail and with higher certainty. 
Making the most of the opportunities offered by precision diabetes medicine will require 
many different stakeholders to form highly effective partnerships. Without networks of 
partnerships that span academic, corporate, payors, regulators, and medical and public 
interest groups with shared understanding and vision (Figure 5), precision diabetes medicine 
is destined to fail. 
People with Diabetes 
People with diabetes are the most important stakeholders. In Western countries, between 
1:10 and 1:20 people suffer from diabetes, while in other parts of the world, diabetes is more 
prevalent (1:3 in some middle-eastern populations (119), and 1:2 in some Native American 
tribes (115)). The precision approach to diabetes will require effective patient-facing, bi-
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directional communication strategies that explain what precision medicine is and how it 
works. Engagement with local patient groups and patient organizations through in-person 
and online forums will be essential. Although patient education will be important, it will be 
equally important to learn from patients, so that precision diabetes medicine is not only 
tailored to a patient’s biology, but also to the socioeconomic and psychosocial characteristics 
that impact therapeutic interventions across the lifespan and across societies. People with 
diabetes should be invited to contribute to postgraduate educational programs for clinicians 
and to have a central role in discussions with politicians, regulators, and payors. 
Regulatory Agencies 
The transition from current diabetes clinical practice to a precision medicine approach will 
have important implications for the development, prescription, and regulation of diagnostics 
and therapeutics. Current evidence evaluation processes are becoming impracticable. As a 
result, regulators are using alternatives, including simulation models, to inform efficacy and 
safety without incurring the cost and complexity of long-term outcomes trials 
(www.fda.gov/science-research/about-science-research-fda/how-simulation-can-transform-
regulatory-pathways). The cost-effectiveness of new drugs developed in the age of precision 
diabetes medicine is uncertain, as the efficacy of those drugs may increase but in smaller 
target groups. Recognizing these challenges, the FDA and the European Medicines Agency 
(EMA) have initiated discussions relating to standards for evidence and the design of future 
clinical trials for precision diabetes medicine (120). Involvement of regulators at the earliest 
stages of the precision diabetes medicine workflow will be critical to the successful 
implementation of the precision approach. 
Payors  
Payment for medical care related to diabetes varies greatly, including between regions within 
countries. Often, costs for diabetes are hidden in other areas of medical care, largely from 
the complexity of treatment and those costs associated with complications of diabetes.  
Fragmentation of sites of delivery for diabetes care and its costs directly impact payment 
policies. Costs need to be directly addressed and involve payors, even if the current cost-
effectiveness of precision diabetes care is largely undetermined. Nevertheless, for precision 
approaches to prevention, diagnosis and treatment of diabetes to be acceptable in most 
clinical settings requires that they are cost-effective. There is evidence in the case of 
monogenic diabetes that this is true (121). The delay, or prevention, of complications (the 
major contributor to diabetes costs) through precision diabetes medicine may be the 
strongest driver for adoption.  
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Industry 
Diabetes technology, including the development of wearable devices for glucose monitoring 
and for regulating insulin infusions (i.e., the artificial pancreas), has developed rapidly and is 
an example of widespread personalized diabetes medicine. In current clinical practice, 
however, technology and pharmaceutical implementation remains at a pre-precision level, as 
guidelines remain fairly generic. Industry and other major stakeholders are focused on 
developing precision diabetes medicine approaches. The European Federation of 
Pharmaceutical Industries and Associations (EFPIA) Diabetes Platform, in which six leading 
pharmaceutical companies are developing shared policy goals focused on improving 
diabetes clinical outcomes, has initiated multiple projects with strong precision diabetes 
medicine agendas. These projects reside under the banner of the Innovative Medicines 
Initiative (IMI), a joint undertaking between public and private sector scientists organized by 
the European Commission. Many other public-private partnerships focused on precision 
diabetes medicine are underway (122). 
Government and Foundation Funders  
Support for diabetes research funding has struggled as its priority has fallen amongst the 
general public and some political decision makers. Despite the enormous burden on 
individuals and society at large, diabetes has struggled for political attention in western 
countries, where cancer and cardiovascular disease rank consistently higher than diabetes 
on the public agenda. An important contributor to this lack of world-wide political engagement 
includes differences in research support, economies and priorities of governments, and 
internal societal factors and needs. Insufficient resources for research are a concern, given 
the public health impact and the influence of diabetes complications on health care cost.  For 
precision diabetes medicine to meaningful improve the lives of patients, it will be necessary 
to build highly-effective networks of key stakeholders, such that common agendas are 
agreed and funding for research and implementation is made available. This in turn requires 
that the evidence justifying a precision diabetes medicine approach is clearly articulated to all 
major decision makers, including funders. 
Clinicians and Professional Organizations  
Medical care for the person with diabetes involves a wide-spectrum of health care providers, 
from tertiary and secondary specialists, general internists, primary care doctors, nurses, 
dietitians, podiatrists, pharmacists, and other paramedical professionals.  Several 
organizations are engaged in the PMDI (ADA, EASD, NIDDK) and representatives of 
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professional bodies in Asia, Africa and elsewhere are being engaged by the PMDI to ensure 
global impact. As outlined earlier in this report, collaborative opportunities are being 
enhanced through the development of new postgraduate educational modules, inclusion of 
precision medicine symposia at sponsored scientific meetings and conferences, and the 
development of a global research network on precision diabetes medicine. Tailoring these 
modules and educational content to different professional and cultural settings is a ideally 
suited to these partner organizations. 
General Public  
The enormous burden that diabetes places on many health care systems is usually 
shouldered by the general public, owing to the high costs of treating the disease and loss of 
public revenue through decreased productivity. As some subtypes of diabetes can, in 
principle, be prevented, intervenion prior to disease onset has great appeal. As the 
prevalence of diabetes is rising rapidly, the current public health strategies appear to be 
failing. The effective implementation of precision prevention will require that the general 
public has the willingness to embrace the approach and that those in greatest need can 
access precision prevention programs. In comparison to other medical conditions, diabetes is 
often perceived by the public as less serious and sympathetic than cancer and 
cardiovascular disease (123), as well as being more stigmatized with obesity. Diabetes 
messaging for the general public can be modeled on precision oncology, for which public 
advocacy and engagement have been successful. In order to reach those who most need of 
precision diabetes medicine, advocates will need to effectively utilize social media as well as 
traditional media to communicate its strengths and weaknesses and its risks and benefits.   
Summary and Future Perspectives 
Precision diabetes medicine has already found a firm foothold in the diagnosis and treatment 
of monogenic diabetes, while the application of precision medicine to other types of diabetes 
is at this time aspirational rather than standard of care. Nevertheless, there are clear 
avenues along which precision medicine may enhance diabetes diagnosis and therapy. 
Future precision diabetes medicine approaches are likely to include diagnostic algorithms for 
defining diabetes subtypes; such algorithms should have most of the characteristics of an 
ideal test and necessary decision support infrastructure if they are to be widely adopted. 
Based upon limited ideal tests and uncertainty in etiology, more research is needed in T1D 
and T2D in order to define subtypes and decide the best interventional and therapeutic 
approaches. The ability to integrate the diagnosis of monogenic diabetes into routine clinical 
care is one example where diagnostics are essential and meet many of the characteristics of 
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the ideal test. Once defined as monogenic diabetes, there is a clear pathway for clinical 
course and treatment, even though considerable work remains on diagnostics. Other areas 
of precision diabetes medicine will need to develop therapeutics and prognosis predication in 
parallel with diagnostic approaches, coupled with evidence of clinical utility and a 
demonstrable benefit in the diagnosis and treatment of the patient. Current diagnostic 
strategies are suboptimal for defining even the major diabetes categories. 
Despite an excellent diagnostic paradigm, there are no known avenues for prevention in 
monogenic diabetes. Similarly, there are no known ways to prevent T1D , although careful 
monitoring in high-risk individuals prevents complications at onset. Thus, precision 
prevention in T1D is likely to involve stratification of at-risk populations within which 
innovative monitoring technologies will be applied. In T2D, lifestyle factors play a dominant 
role, yet standardized preventive interventions have relatively low efficacy. Although both 
lifestyle and pharmaceutical interventions can delay onset of diabetes in people at high-risk 
(e.g., those with obesity and impared glucose tolerance), completely preventing diabetes has 
proven challenging. Nevertheless, because lifestyle is paramount and there are such variable 
responses to lifestyle interventions, opportunities for precision prevention of T2D are perhaps 
most apparent, with some studies showing that tailoring diet to an individual’s biological 
characteristics can help minimize postprandial glucose excursions (84). The scope and 
potential for precision treatment in diabetes is vast, yet deep understanding is lacking.  For 
drug outcomes, there is a pressing need to move beyond early glycemic response and 
examine variation in response in terms of cardiovascular outcomes, mortality and other 
patient-centered outcomes, especially for the newer agents such as SGLT2i and GLP-1RA. It 
will be imperative to determine when and how the application of therapeutics in precision 
diabetes medicine improves outcomes in a cost-effective fashion.  
There are many important stakeholders whose engagement will be necessary for the 
implementation of precision diabetes medicine to succeed (Figure 5). Progress in translating 
advances in biology and technology will be governed by the identification, accurate 
measurement and scalable deployment of agents for diagnosis and therapy, so broad 
stakeholder engagement is essential. It is crucial that precision approaches are available to 
the full diversity of human populations and societal contexts, such that precision diabetes 
medicine does not widen health disparity but achieves the greatest benefits to all individuals 
and society as a whole. Highly functional partnerships with patient representatives and public 
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Text box 1: DEFINITIONS.   
o Definition. Precision diagnosis involves refining the characterization of 
the diabetes diagnosis for therapeutic optimization or to improve 
prognostic clarity using information about a person’s unique biology, 
environment and/or context.  
o Precision diagnostics may involve subclassifying the diagnosis into 
subtypes, such as is the case in MODY, or utilizing probabilistic 
algorithms that help refine a diagnosis without categorization.  
o Careful diagnosis is often necessary for successful precision therapy, 
whether for prevention or treatment. This is true where subgroup(s) of the 
population must be defined, within which targeted interventions will be 
applied and also where one seeks to determine whether progression 
toward disease has been abated.  
o Precision diagnosis can be conceptualized as a pathway, rather than a 
single step, that moves through stages. The diagnostic stages include i) 
an evaluation of prevalence based on epidemiology, including age, or age 
at diagnosis of diabetes, sex and ancestry; ii) probability based on clinical 
features; and iii) diagnostic tests that are interpreted in the light of i) and 
ii). A diagnosis in precision medicine is a probability-based decision, 
typically made at a specific point in the natural history of a disease, and 
neither an absolute truth nor a permanent state. 
o Definition. Precision therapeutics involves tailoring medical approaches 
using information about a person’s unique biology, environment and/or 
context for the purposes of preventing or treating disease (see precision 
prevention and precision treatment).  
o Definition. Precision prevention includes using information about a 
person’s unique biology, environment and/or context to determine their 
likely responses to health interventions and risk factors and/or to monitor 
progression toward disease.  
o Precision prevention should optimize the prescription of health enhancing 
interventions and/or minimize exposure to specific risk factors for that 
individual. Precision prevention may also involve monitoring of health 
markers or behaviors in people at high risk of disease, to facilitate 
targeted prophylactic interventions. 
 30 
o Definition. Precision treatment involves using information about a 
person’s unique biology, environment and/or context to guide the choice 
of an efficacious therapy to achieve the desired therapeutic goal or 
outcome, while reducing unnecessary side effects. 
o Today, the objective of precision therapy is to maximize the probability 
that the best treatment of all those available is selected for a given patient. 
It is possible that in the future, precision diabetes medicines will be 
designed according to the biological features of specific patient 
subgroups, rather than for the patient population as a whole. 
o Definition. Precision prognostics focuses on improving the precision and 
accuracy with which a patient’s disease-related outcomes are predicted 
using information about their unique biology, environment and/or context.  
o The focus of precision prognostics includes predicting the risk and 
severity of diabetes complications, patient-centered outcomes, and/or 
early mortality 
o Definition. Precision monitoring may include the detailed assessment of 
biological markers (e.g., continuous glucose monitoring), behaviours (e.g., 
physical activity), diet, sleep, and psychophysiological stress.  
o Precision monitoring can be achieved using digital apps, cutaneous or 
subcutaneous sensors, ingestible sensors, blood assays etc.  
o The intelligent processing, integration and interpretation of the data 
obtained through precision monitoring are key determinants of success 
o Precision monitoring may be valuable for precision prevention (e.g., in 
T1D), precision diagnostics (e.g., where diagnoses are based on time-
varying characteristics) and precision prognostics (e.g., where disease 
trajectories are informative of the development of key outcomes). 
 
Text box 2: PRECISION DIAGNOSTICS: BACKGROUND, BARRIERS TO 
IMPLEMENTATION AND RESEARCH GAPS     
o Type 1 Diabetes.  Best diagnostic results depend on integrating all 
diagnostic modalities, not by relying on prior prevalence, clinical features, 
or test results in isolation. The age at which the initial islet autoantibody 
appears and the type of autoantibody (e.g., which of the four primary 
antibodies among ICA512, Ins, GAD, ZnT8) may be important in defining 
etiological subtypes of T1D. The majority of the genetic risk of T1D is now 
known, and the sensitivity and specificity of a T1D polygenic score (T1D-
PS) exceed 80%. Despite this, a high T1D-PS will have low positive 
predictive value in patient populations where the overall prevalence of 
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T1D is low, such as those aged >50 years when diabetes is diagnosed. It 
will likely prove most useful when the T1D-PS is combined with clinical 
features and islet autoantibodies. At present, there is no immune-based 
test sufficiently reproducible and robust that it can be used diagnostically 
o Type 2 Diabetes. Categories based on cluster analysis at diagnosis can 
provide insights into likely progression, risk of complications, and 
treatment response, which offer an exciting approach to subclassification 
of T2D. At this time, the available genetic data for T2D does not have 
sufficient predictive accuracy to replace existing delineative approaches. 
Although the subcategorization of T2D using genetic data is informative of 
the etiological processes that underlie the disease, the methods described 
so far (77; 78) are not intended to be used to subclassify a T2D diagnosis 
nor are the existing genetic data sufficient for this purpose for the majority 
of patients with T2D. Treatment response and progression can be 
predicted from clinical features (36). An advantage of using clinical 
features for diagnosis of T2D is that they are widely available and easily 
obtained (e.g., sex, BMI, HbA1c); however, a potential limitation is that 
they may be time varying.   
o Barriers to implementation.  One of several important translational barriers 
facing the proposed clustering approach for T1D and T2D is that a fasting 
C-peptide is required at the time of diagnosis, which is not routinely 
performed in clinical practice and the reliability of C-peptide assays vary 
considerably between labs (35). Another limitation is that the biomarkers 
used to define these clusters change in time depending on the disease 
course or its treatment, such that this approach can only be applied to 
newly diagnosed cases, but not to individuals years before disease onset 
or the many millions of people with long-standing diabetes worldwide. 
Moreover, because the current approaches for clustering in T2D require 
continuously distributed data to be categorized, which typically results in 
loss of power, these methods do not yield good predictive accuracy, a 
major expectation in precision medicine, but this may change as the 
approach is refined 
o Research gaps.  Based upon limited ideal tests and uncertainty in 
etiology, more research is needed in T1D and T2D in order to define 




Text box 3: PRECISION PREVENTION: BACKGROUND, BARRIERS TO 
IMPLEMENTATION AND RESEARCH GAPS     
o Type 1 Diabetes.  In T1D, precision prevention mainly involves the 
optimization of monitoring methods, thereby facilitating early detection and 
treatment. The reasons most prevention trials in T1D have not been 
effective may include failure to consider the individual’s unique T1D risk 
profile (e.g., genetic susceptibility) and their unique response to the 
preventive agent (immune therapy or dietary intervention). Without 
considering the unique genetic profiles of children, interventions aimed at 
preventing type 1 diabetes (e.g., dietary intervention or immunotherapy) 
may be unlikely to succeed. Thus, precision prevention in T1D is likely to 
involve stratification of at-risk populations and innovative monitoring 
technologies. 
o Type 2 Diabetes. T2D has many avenues for prevention and thus the 
possibilities for precision approaches, possibly through tailoring of diet, 
are broad. To date, prevention of type 2 diabetes has focused on people 
with prediabetes. To be cost-effective, it is likely necessary to stratify the 
prediabetic population such that only in those with other relevant risk 
factors be the focus of preventative interventions. Relevant risk factors 
may include lifestyle, socioeconomic status, family history, ethnicity and/or 
certain biomarker profiles, including genetics). 
o Barriers to implementation.  The effective implementation of precision 
prevention will require that appropriate technologies are available, the 
general public has the willingness to embrace the approach, and that 
those in greatest need can access precision prevention programs. A 
communication plan used by the interventionalist and the patient’s 
perception of risk should be a focus of precision prevention strategies.  
o Research gaps.  There are critical areas of research required for 
implementation of precision prevention in diabetes, including determining 
for whom online care is more effective than in-person care, the types of 
staff delivering the lifestyle modification programs, the impact of group 
and/or individual interaction, and the frequency of such sessions. There is 
also uncertainty about how best to provide and sustain lifestyle 
modification. Additionally, emphasis should be placed on identifying 
profiles that indicate likely response to specific lifestyle interventions 
(focusing on specifc diets, exercise programs and other behavioural 
factors) and sensitivity to risk factors (such as sleep disturbance, stress, 
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Text box 4: PRECISION MEDICINE APPROACHES TO TREAT DIABETES: 
BACKGROUND, BARRIERS TO IMPLEMENTATION AND RESEARCH GAPS   
o Type 1 diabetes. In T1D, the only existing therapy is insulin. 
Developments in long-acting and glucose sensitive insulins are improving 
the health and wellbeing of people with T1D, as are technological 
advances in the artificial pancreas.  
o Type 2 diabetes. It has long been recognized that T2D is heterogeneous 
in its etiology, clinical presentation and pathogenesis. Yet, traditionally, 
trials of therapeutic intervention do not recognize this variation.  
o With increasing efforts to map patients with T2D in etiological space using 
clinical and molecular phenotype, physiology and genetics it is likely that 
this increasingly granular view of T2D will lead to increasing precision 
therapeutic paradigms requiring evaluation and potential implementation. 
Genetic variation not only can capture etiological variation (i.e., genetic 
variants associated with diabetes risk) but also variation in drug 
pharmacokinetics (absorption, distribution, metabolism, excretion – 
ADME) and in drug action (pharmacodynamics).  
o In contrast, ‘true’ T2D is a common complex disease characterized by 
thousands of etiological variants, each contributing to a small extent to 
diabetes risk. Thus, it remains uncertain that genetic variants will be 
identified that are highly predictive of drug outcomes in T2D, even if 
process-specific polygenic risk scores are derived (where all variants on 
an etiological pathway are combined to increase power). 
o Barriers to implementation. The current and growing burden of diabetes is 
not from western white populations but from other ethnic groups, in 
particular South and East Asians. Yet, these populations are under-
represented in clinical trials and, in particular, in attempts to understand 
variation in drug outcomes.  
o Because the diabetes phenotype can vary markedly by ethnic group, it is 
likely that complications and drug outcomes will differ between 
populations. 
o Many of the approaches gaining traction in precision medicine generate 
massive datasets that are burdensum to store and require powerful 
computational servers for analysis. 
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o Undertaking appropriately designed clinical trials for precision treatments 
that meet the current expectations of regulatory authorities may be 
challenging, given the many subgroups within which treatments will need 
to be evaluated. Innovative clinical trials will likely be needed and real-
world evidence will likely need to be part of the evaluation process.   
o Research gaps.  For drug outcomes, there is a pressing need to move 
beyond early glycemic response and examine variation in response in 
terms of cardiovascular outcomes and mortality, especially of the newer 
agents such as SGLT2i and GLP-1RA, with focus on specific patient 
subgroups. Identifying predictive markers (especially genetic markers) of 
serious adverse events in patients treated with these drugs presents an 
additional area urgently in need of greater attention. 
o Need for better understanding of the pathophysiology of diabetes to 
inform on new therapeutic targets  
o Need to study broader populations/ethnic groups 
o Need for understanding outcomes of highest relevance to patients 
o Need for decision support tools to implement precision diabetes medicine 
in clinical practice  
o Need to demonstrate that approaches are cost-effective 
 
 
Text box 5: PRECISION MEDICINE APPROACHES TO LESSEN TREATMENT 
BURDEN AND IMPROVE QUALITY OF LIFE.   
o Diagnosis.  A more specific diagnosis has the potential to reduce 
uncertainty and manage future expectations about disease course.  This 
is clearly the case for some monogenic forms of diabetes, where 
diagnosis is nearly certain, given its strong genetic indication, and the 
specific treatment is coupled to the subcategory (genetic subtype) of 
disease.  Emerging knowledge regarding subtypes of T2D has the 
potential to classify individuals with diabetes with risk for progression to 
complications. 
o Misdiagnosis.  Inaccurate classification of the type of diabetes, either from 
lack of precision or inadequate clinical attention to detail at the time of 
presentation, can have long-lasting, adverse effects on mental health and 
quality of life.  In the pediatric and younger adult population, the risk of 
misclassification is increasing as both “true” T1D and “true” T2D 
classifications are confused through the growing obesity epidemic in youth 
(T2D) and older onset ages (T1D). In addition, monogenic variants of 
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diabetes can be misdiagnosed as either T1D or T2D.  A precision 
approach to diagnosis with appropriate standardized laboratory support 
and increased research to obtain novel biomarkers of disease has the 
potential to solve this problem. 
o Complications.  Worry about complications is an issue for all people with 
diabetes. Currently, having diabetes (either T1D or T2D) is given a label 
of being unequivocally at risk of reduced lifespan, amputation, kidney 
failure, and blindness.  A more precise diagnosis, prognosis, and strategy 
to predict and prevent complications has the potential to greatly reduce 
disease burden, distress, and improve quality of life. Nevertheless, there 
is also a risk that more precise prognistification may cause distress if the 
options for successful intervention are limited or incompatible with the 
patient’s needs or desires. 
o Stigmatization.  A major burden for people with diabetes is that the 
disease is often considered the fault of the patient. This is particularly true 
for T2D, as it is often labelled as ‘just’ a lifestyle disease. Clinical care of 
those with diabetes often results in a singular approach to treatment, 
regardless of their specific needs, life situation, and other conditions. A 
clinical process that makes diagnosis more precise and includes the 
patient-oriented evaluation and response to needs has the potential to 









Figure 1 . Precision Medicine in Diabetes Initiaitve (PMDI) Activities 
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Figure 3 – Precision Therapeutics 
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